All In Biotech

NDA 216016 · Bracco

Iomervu

Iomeprol · Intra-Arterial · Radiographic Contrast Agent

Novel

Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Nov 27, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

0 Phase 3, 1 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION Intrathecal administration, even if inadvertent, may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. IOMERVU is for intra-arterial or intravenous use only [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 )]. WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION Intrathecal administration, even if inadvertent, may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. IOMERVU is for intra-arterial or intravenous use only. (2.1, 5.1)

What it is approved for

From the label in effect Feb 5, 2026.

IOMERVU is a radiographic contrast agent indicated for: Intra-arterial Procedures † ( 1.1 ) Cerebral arteriography, includingintra-arterial digital subtraction angiography (IA-DSA), in adults and pediatric patients Visceral and peripheral arteriography and aortography, including IA-DSA, in adults and pediatric patients Coronary arteriography and cardiac ventriculography in adults Radiographic evaluation of cardiac chambers and related arteries in pediatric patients Intravenous Procedures † ( 1.2 ) Computed tomography (CT) of the head and body in adults and pediatric patients CT angiography of intracranial, visceral, and lower extremity arteries in adults and pediatric patients Coronary CT angiography in adults and pediatric patients CT urography in adults and pediatric patients † Specific concentrations are recommended for each type of imaging procedure. ( 2.2 , 2.3 , 2.4 , 2.5 ) 1.1 Intra-arterial Procedures † IOMERVU is indicated for: Cerebral arteriography, including intra-arterial digital subtraction angiography (IA-DSA), in adults and pediatric patients Visceral and peripheral arteriography and aortography, including IA-DSA, in adults and pediatric patients Coronary arteriography and cardiac ventriculography in adults Radiographic evaluation of cardiac chambers and related arteries in pediatric patients 1.2 Intravenous Procedures † IOMERVU is indicated for: Computed tomography (CT) of the head and body in adults and pediatric patients CT angiography of intracranial, visceral, and lower extremity arteries in adults and pediatric patients Coronary CT angiography in adults and pediatric patients CT urography in adults and pediatric patients † Specific concentrations of IOMERVU are recommended for each type of imaging procedure [see Dosage and Administration ( 2.2 ,...

Mechanism: Iomeprol is a radiographic iodinated contrast agent that opacifies the vessels and body structures where the contrast agent is present following intravenous or intra-arterial administration, permitting radiographic visualization of the internal structures through attenuation of X-ray photons. In imaging of the body, iodinated contrast agents diffuse from the vessels into the extravascular space. In normal brain with an intact blood-brain barrier, the contrast agent does not diffuse into the extravascular space and contrast enhancement is generally due to the presence of contrast within the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 27, 2024 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
13 products under this application
  • IOMERVU · IOMEPROL 52.5GM IODINE/150ML (350MG IODINE/ML · SOLUTION, INTRA-ARTERIAL · Discontinued
  • IOMERVU · IOMEPROL 17.5GM IODINE/50ML (350MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
  • IOMERVU · IOMEPROL 60GM IODINE/150ML (400MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
  • IOMERVU · IOMEPROL 45GM IODINE/150ML (300MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
  • IOMERVU · IOMEPROL 20GM IODINE/50ML (400MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
  • IOMERVU · IOMEPROL 15GM IODINE/50ML (300MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
  • IOMERVU · IOMEPROL 70GM IODINE/200ML (350MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Prescription
  • IOMERVU · IOMEPROL 35GM IODINE/100ML (350MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Prescription
  • IOMERVU · IOMEPROL 80GM IODINE/200ML (400MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Prescription
  • IOMERVU · IOMEPROL 60GM IODINE/200ML (300MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
  • IOMERVU · IOMEPROL 40GM IODINE/100ML (400MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Prescription
  • IOMERVU · IOMEPROL 30GM IODINE/100ML (300MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued
  • IOMERVU · IOMEPROL 25GM IODINE/100ML (250MG IODINE/ML) · SOLUTION, INTRA-ARTERIAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Iomeprol" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 90 on PubMed

Sponsor: Bracco

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.